Skip to main navigation
  • Back to SpringWorksTx.com
  • Investors & Media
  • Contact Us
  • Linkedin
  • Twitter
SpringWorks
  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
  • Corporate Governance
  • Financial Information
    • SEC Filings
    • Annual Reports
  • Stock Information
    • Stock Quote & Chart
    • Analyst Coverage
  • Investor Resources
    • Investor FAQs
    • Investor Contacts
    • Email Alerts
  • Investors + Media
  • Medical Professionals
  • Contact Us
  • Linkedin
  • Twitter

Event Details

OGSIVEO™ FDA Approval Call

Nov 28, 2023 at 8:00 AM EST

View the Webcast

Supporting Materials

View Presentation 3.8 MB

Springworks - Toolkits

  • Print Page
  • Email Alerts
  • RSS Feeds
  • Investor Contacts

Springworks Logo

Social Links

  • linkedin
  • twitter
Footer 1
  • Who We Are
    • Leadership & Board
    • Mission & Values
    • DE&I
    • Partners & Collaborators
  • Focus Areas
    • Rare Oncology
    • BCMA Combinations in Multiple Myeloma
    • Biomarker-Defined Metastatic Solid Tumors
Footer 2
  • Pipeline
    • Nirogacestat
    • Mirdametinib
    • Clinical Trials
    • Investigator-Initiated Research
    • Key Scientific Presentations and Publications
  • Careers
    • View Opportunities
Footer 3
  • Patients
    • Desmoid Tumors
    • NF1-PN
    • Expanded Access
  • Contact
Footer 4
  • Investors & Media
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financial Information
    • Stock Information
    • Investor Resources

© 2024 SpringWorks Therapeutics. All rights reserved.

Copyright Links

  • Privacy Policy
  • Terms of Use
  • Cookie Policy